Abstract
Inhibition of plasma kallikrein (pKal) activity is a validated mechanism for prevention of HAE attacks. High potency and long duration of action are key drivers of prophylactic efficacy of pKal inhibitors but both attributes are not currently available in the same HAE treatment. We sought to generate a monoclonal antibody (mAb) pKal inhibitor with both high potency and long duration of action.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
